ENLIVEX THERAPEUTICS LTD ENLV 深 沪
等待开盘 09-06 09:30:00 美东时间
1.06
-0.010
-0.93%
华盛通- 最 高1.08
- 今 开1.06
- 成交量 18.56万股
- 最 低 1.05
- 昨 收 1.07
- 总市值 2528.09万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8101
- 委 比 93.47%
- 总股本 2384.99万
- 历史最高 44.90
- 量 比 0.77
- 振 幅 2.80%
- 历史最低 0.8101
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7 price target.
09-02 19:16
Enlivex’s Allocetra: A New Hope for Psoriatic Arthritis?
Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical st...
08-21 00:16
Enlivex to Present Key Results from Osteoarthritis Trial
An update from Enlivex ( ($ENLV) ) is now available. On August 14, 2025, Enlive...
08-14 20:57
Enlivex To Present 3-Month Topline Data From Phase IIa Stage Of Its Phase I/IIa ENLX-CL-05-001 Trial
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis
08-14 20:43
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Enlivex Therapeutics Ltd. will host a webinar on August 18, 2025, at 8:00 AM ET to discuss the 3-month top-line results from the Phase IIa stage of its ENX-CL-05-001 trial, evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. The webinar will feature a detailed analysis of the data from the multi-center, randomized, placebo-controlled study. Osteoarthritis affects millions globally, and knee osteoarthritis is particularl...
08-14 12:30
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Enlivex Therapeutics Ltd. announced that all 134 patients in its Phase II trial of Allocetra™ for moderate to severe knee osteoarthritis have completed at least three months of follow-up, with audited topline results expected on August 18, 2025. The Phase I/II trial evaluates safety and efficacy endpoints, including knee pain and function, at three, six, and 12 months. Currently, no approved treatments slow joint damage in osteoarthritis. Enlivex...
07-28 12:30
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.
07-22 20:14
Enlivex Therapeutics To Feature Data From Ongoing Clinical Study Evaluating Proprietary Allocetra Off-The-Shelf Macrophage Reprogramming Cell Therapy, In Patients With Knee Osteoarthritis At EULAR European Congress Of Rheumatology
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for
06-10 20:34
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Enlivex Therapeutics will present data on theirAllocetra™ cell therapy for knee osteoarthritis at the EULAR Congress in Barcelona. The Phase I/II trial shows promising safety and efficacy, including pain reduction and improved joint function. Enrollment for the Phase II stage is complete, with topline data expected by August 2025. Company executives will attend the conference. --- 总结：Enlivex将在巴塞罗那的EULAR大会上展示其用于膝关节骨关节炎的Allocetra™细胞疗法数据。I/II期试验显示...
06-10 12:30
国投证券-生物医药行业新药周观点：脓毒症治疗迎来新突破，远大医药STC3141中国2期成功-250518
（转自：研报虎） 本周新药行情回顾： 2025年5月12日-2025年5月16日，新药板块涨幅前5企业：君圣泰(19.78%)、德琪医药(18.34%)...
05-18 17:56
